Skip to main content
. Author manuscript; available in PMC: 2018 Dec 1.
Published in final edited form as: Mol Cancer Res. 2017 Sep 14;15(12):1741–1751. doi: 10.1158/1541-7786.MCR-17-0010

Figure 6. PRELID1 APA and expression influences outcomes in multiple cancers.

Figure 6

A–B. PRELID1 APA-associated outcomes: overall survival, split by median PRELID1 Exon 4/Exon 5 ratio in PRELID1-associated (A) and PRELID1-independent (B) tumors. C. PRELID1 expression-associated outcomes: overall survival, split by median PRELID1 Exon 4 expression. Dashed grey line is “Short PRELID1” (APA; A–B) or “High PRELID1” (Expression; C), black line is “Long PRELID1” (APA; A–B) or “Low PRELID1” (Expression; C).